Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 10/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | OXTR | P30559 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962344 | 0.82 | LMNA (0.56) | ALDH1A1SMN1; SMN2GAAHTT | |
| SCHEMBL6405987 | 0.82 | AVPR1A (0.53) | AVPR1AKCNH2ALDH1A1SMN1; SMN2OXTR | |
| SCHEMBL4965179 | 0.79 | SMN1; SMN2 (0.50) | AVPR1AKCNH2ALDH1A1SMN1; SMN2OXTR | |
| SCHEMBL4966313 | 0.79 | HDAC4 (0.49) | AVPR1AKCNH2ALDH1A1SMN1; SMN2OXTR | |
| SCHEMBL4963772 | 0.78 | TRPA1 (0.53) | AVPR1AKCNH2ALDH1A1SMN1; SMN2OXTR | |
| SCHEMBL6405064 | 0.78 | AVPR1A (0.49) | AVPR1AKCNH2ALDH1A1SMN1; SMN2OXTR | |
| SCHEMBL4830008 | 0.77 | CNR1 (0.57) | — | |
| SCHEMBL6406749 | 0.77 | AVPR1A (0.48) | AVPR1AKCNH2ALDH1A1SMN1; SMN2OXTR | |
| SCHEMBL6405946 | 0.77 | AVPR1A (0.48) | AVPR1AKCNH2ALDH1A1SMN1; SMN2OXTR | |
| SCHEMBL9893002 | 0.77 | ACACB (0.82) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AVPR1A 57/4885KCNH2 2120/4885ACACB 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.